Context: Adrenocortical carcinoma (ACC) is rare and confers an unfavorable prognosis in advanced stages. Other than combination chemotherapy with cisplatin, etoposide, doxorubicin, and mitotane, the second-and third-line regimens are not well-established. Gemcitabine (GEM)-based chemotherapy was suggested in a phase 2 clinical trial with 28 patients. In other solid tumors, human equilibrative nucleoside transporter type 1 (hENT1) and/or ribonucleotide reductase catalytic subunit M1 (RRM1) expression have been associated with resistance to GEM.
Conclusions: GEM-based chemotherapy is a well-tolerated, but modestly active, regimen against advanced ACC. No reliable molecular predictive factors could be identified. Owing to the scarce alternative therapeutic options, GEM-based chemotherapy remains an important option for salvage treatment for advanced ACC. (J Clin Endocrinol Metab 102: [4323] [4324] [4325] [4326] [4327] [4328] [4329] [4330] [4331] [4332] 2017) A drenocortical carcinoma (ACC) is a rare and highly malignant tumor with a generally poor prognosis. The initial tumor stage is the single most important prognostic factor with an overall 5-year survival of ,15% in the presence of metastasis (1) (2) (3) (4) . Systemic treatments for advanced disease are very limited and usually include mitotane, either alone or combined with chemotherapy (5, 6) . According to the results of the first randomized controlled phase 3 clinical trial [FIRM-ACT (Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment)], combination chemotherapy with etoposide, doxorubicin, cisplatin, and mitotane represents the current first-line treatment in advanced ACC (7) . In a phase 2 clinical trial, 28 patients with advanced ACC were treated with gemcitabine (2 0 ,2 0 -difluorodeoxycytidine; GEM) (8) , which has been proposed as a second-line option combined with fluoropyrimidines (capecitabine or 5-fluorouracil) (6) . In this pilot study, the proportion of patients without progression after 4 months of treatment was 46%, with a median interval to progression of 5.3 months, including a complete and partial response in 1 patient each. Since then, GEM-based chemotherapy has found widespread use in view of the absence of established second-and third-line treatments. To date, however, the promising findings of the phase 2 trial have not been confirmed in any other series (9) . Moreover, to date, no reliable predictive biomarkers are available, impeding the identification of potentially responsive patients.
The predictive role of molecules involved in the metabolism of GEM has already been investigated in various solid tumors. For instance, the human equilibrative nucleoside transporter type 1 (hENT1) mediates cellular entry of nucleosides (10) , including some cytotoxic nucleoside analogs, such as cytarabine, fludarabine, and GEM (11, 12) . hENT1 deficiency impairs efficacy of nucleotide drugs both in vitro (12) and in vivo, as repeatedly demonstrated in different solid cancer types such as pancreatic cancer (13) (14) (15) , biliary tract cancer (16, 17) , and bladder cancer (18) . Another promising biomarker is the subunit of ribonucleotide reductase [ribonucleotide reductase catalytic subunit M1 (RRM1)], which catalyzes the rate-limiting step in the production of deoxyribonucleotides. The latter are essential for DNA synthesis and repair and, thus, representing another important cellular determinant of GEM efficacy. Previous studies have demonstrated that low RRM1 expression levels are associated with a better response to GEM-containing treatment regimens in different tumor types (19, 20) and to adjuvant treatment with mitotane in ACC (21) .
Thus, the major goal of the present retrospective multicenter study was to assess the efficacy and safety of GEMbased chemotherapy in a large series of patients with advanced ACC. Moreover, we investigated the expression of both hENT1 and RRM1 in adrenocortical tissues and their prognostic and predictive role.
Material and Methods
The local ethics committee approved the collection of clinical data and biomaterial for the present retrospective study in accordance with the principles of the Declaration of Helsinki. All included patients provided written informed consent.
Patients and Treatment Regimen
The inclusion criteria for the study were age $18 years, histologic diagnosis of ACC, and treatment with GEM according to clinical practice. We identified 155 patients who had advanced ACC and had undergone GEM-based chemotherapy (at least one administration of intravenous GEM) at our referral centers from January 2004 to December 2016 (Germany, n = 124; Italy, n = 31) and were not a part of a previously reported series (8) . Of these 155 patients, 10 were lost to followup and were excluded from further analysis. Thus, a final series of 145 patients with advanced ACC were included in the present study. The baseline clinical parameters, such as initial tumor size, tumor stage at the diagnosis according to the European Network for the Study of Adrenal Tumors (ENSAT) classification (3), hormonal secretion pattern, Weiss score, Ki67 proliferation index, presence and number of distant metastases, and previous treatments, are listed in Table 1 . All data were collected through the ENSAT Registry (available at: www.ens@ t.org/registry). Detailed follow-up data during GEM-based treatment were collected from the patients' medical records. In brief, the standard treatment scheme consisted of 800 mg/m 2 intravenous GEM on days 1 and 8, repeatedly administered in 21-day cycles, as an infusion over 30 minutes. The median number of GEM cycles was 4 (range, 1 to 31). Altogether, 132 patients (91.0%) received a combination of oral capecitabine (1500 mg daily) (8), 7, a combination of oral erlotinib (100 mg daily) (9), 3, a combination with other drugs (i.e., vinorelbine, carmustine, or 5-fluorouracil), and 3, gemcitabin alone. Moreover, 114 patients (78.6%) were concomitantly treated with mitotane, with a target plasma concentration of 14 to 20 mg/L. The exact mitotane concentrations were available for 89 patients, of which, 42 had reached the "target plasma level" of $14 mg/L (47.2%). Only one patient received GEM as monotherapy. Finally, GEM-based chemotherapy was administered as first-line treatment to 12 patients (8.3%) and as second-line treatment to 83 patients (after former treatment failure of platinum-based chemotherapy or streptozotocin in 81 and 2 patients, respectively). The remaining 50 patients received GEM-based chemotherapy as third-to fifth-line therapy, with a history of failed platinum-based chemotherapy, streptozotocin, sunitinib (multitargeted receptor tyrosine kinase) (22) , linsitinib (insulin-like growth factor 1 receptor and insulin receptor inhibitor) (23) , trofosfamide (24) , or thalidomide ( Table 1) .
Evaluation of response and toxicity
All 145 patients underwent standardized follow-up visits, with a staging examination usually every 8 to 12 weeks. These evaluations included physical examination, biochemical workup (with routine chemistry and steroid hormone test), and multislice imaging (usually contrast-enhanced computed tomography) of the chest and abdomen. Treatment was discontinued in the case of unacceptable toxicity, patient refusal, or evidence of disease progression.
The efficacy of GEM-based chemotherapy was retrospectively assessed by progression-free survival (PFS; defined in the Statistical analysis section) and best overall objective response. For this evaluation, according to our clinical practice, all radiological images were reviewed by the local expert radiologists and discussed at our multidisciplinary tumor board meetings to determine a final consensus response (progressive disease, stable disease, or partial or complete response). Clinical benefit was defined as stable disease or a treatment response for a minimum of 4 months.
Potential treatment-related adverse effects were regularly recorded during the follow-up visits and retrospectively summarized from the patients' medical records. The toxicities were graded using the Common Terminology Criteria for Adverse Events, version 4.03.
Formalin-fixed paraffin-embedded tissue samples and immunohistochemistry
The series of formalin-fixed paraffin-embedded (FFPE) specimens included 303 ACC samples (52 standard slides and 251 assembled into seven tissue microarrays) from 262 patients, 51 adrenocortical adenoma cases, and 18 normal adrenal gland samples (including 3 cases of adrenal hyperplasia; Supplemental Table 1 ). Of the 303 ACC samples, 87 were from 70 of the 145 patients who had received GEM-based chemotherapy in the present study. For 17 cases, we had FFPE material available from subsequent surgeries in the same patients (primary tumor and local recurrence and/or distant metastasis). The baseline clinical characteristics of these patients (median age, 43 years; median tumor size, 12.5 cm; median Weiss score, 6; median proliferation index Ki67, 20%) were similar to those of the other 75 patients without available FFPE material. The remaining 216 FFPE tumor specimens were from 192 patients (117 females and 75 males; median age at diagnosis, 50 years; range, 17 to 81), who had not received GEM-based chemotherapy (Supplemental Table 1 ). In the present series of patients, 88 had ENSAT stage I to II (48.9% of known), 53 had ENSAT stage III (29.4%), and 38 had ENSAT stage IV (21.1%). The median Weiss score was 5 (range, 2 to 9), and the median Ki67 was 10 (range, 1 to 80). The entire series was included to investigate hENT1 and RRM1 expression using immunohistochemistry.
The tissue microarrays and full sections were deparaffinized, and immunohistochemical detection was performed using an indirect immunoperoxidase technique after high temperature All slides were analyzed independently by two investigators who were unaware of the clinical information (J.E.K.H. and C.L.R.), with evaluation of membranous staining for hENT1 and cytoplasmic staining for RRM1. The membranous hENT1 staining intensity was classified as negative (score, 0) or positive (score 1). The RRM1 staining intensity in the cytoplasm was graded as negative (score, 0), low (score, 1), medium (score, 2), or strong (score, 3). The percentage of positive tumor cells was calculated for each specimen and scored as 0 if 0% were positive, 0.1 if 1% to 19% were positive, 0.5 if 20% to 49% were positive, and 1 if $50% were positive. A semiquantitative H-score was then calculated by multiplying the staining intensity grading score with the proportion score, as described previously (25) . In the case of discrepant results, the staining intensities were jointly assessed by both investigators, with the final score determined by consensus. Interobserver agreement was investigated using Pearson correlation coefficients: 0.66 [95% confidence interval (CI), 0.59 to 0.71] for hENT1 and 0.62 (95% CI, 0.56 to 0.68) for RRM1. Both hENT1 and RRM1 were homogeneously distributed, with a percentage of positive cells .50% in 86% and 76% of samples, respectively.
Statistical analysis
The Fisher exact test or x 2 test was used to investigate dichotomous variables, and continuous variables were investigated using a two-sided t test or nonparametric test. A nonparametric Kruskal-Wallis test, followed by the Dunn test, was used for comparisons among several groups for nonnormally distributed variables. The correlations and 95% CIs between different parameters were evaluated using linear regression analysis.
PFS was defined as the interval from the date of primary tumor resection or the start of GEM therapy (as indicated) to the first radiological evidence of disease progression or death. Similarly, disease-specific survival was defined as the interval from the date of primary surgery or the start of GEM therapy (as indicated) to disease-specific death or the last follow-up visit. Survival curves were obtained with Kaplan-Meier estimates, and the differences between survival curves were assessed using the log-rank (Mantel-Cox) test. For the calculation of hazard ratios (HRs), two ACC groups with negative/low or positive/ high hENT1 and RRM1 protein expression, respectively, were considered. A multivariate regression analysis was performed using a Cox proportional hazard regression model to identify factors that might independently influence survival.
Statistical analyses were performed using GraphPad Prism, version 6.0 (GraphPad, La Jolla, CA) and SPSS software, PASW version 21.0 (IBM Corp., Armonk, NY). P , 0.05 was considered statistically significant.
Results

Efficacy and tolerability of GEM-based chemotherapy
Detailed characteristics of the 145-patient cohort (85 women, 60 men; mean 6 standard deviation age at diagnosis, 45.4 6 13.4 years) are given in Table 1 . The median PFS was 12 weeks [90 days; range 1 to 94 weeks (7 to 658 days); Fig. 1A ]. During the study or follow-up period, 116 patients had died, and all but one had died of progressive ACC. The median disease-specific survival after the initiation of GEM treatment was 40 weeks (range 1 to 280; Fig. 1A ). Four patients did not receive the second cycle of GEM because they had died of ACC unrelated to treatment after 7 to 21 days of the first cycle (n = 3) or because of clinically evident disease progression confirmed by early imaging studies (n = 1).
Considering the best objective response to therapy (n = 144; Table 1 No statistically significant differences were observed between patients who had received GEM-based chemotherapy as first-or second-line treatment or in a later treatment line (P = 0.55). However, patients with concomitant mitotane that reached the target concentration of .14 mg/L (n = 42) had a longer PFS than those in whom it had not (n = 47) and compared with those who had not received mitotane (n = 21; HR for progression, 0.56; 95% CI, 0.35 to 0.77; P = 0.0026; Supplemental Fig. 1A) . Similar results were obtained in terms of the objective response (Supplemental Fig. 1B) . Finally, a longer PFS during treatment was observed for patients receiving capecitabine combined with GEM compared with the other patients (HR for progression, 0.55; 95% CI, 0.19 to 0.84; P = 0.026).
Data on toxicity were available for 109 of the 145 patients (75.2%). In general, GEM was well tolerated with severe adverse events (Common Terminology Criteria for Adverse Events grade 3 to 4) reported in 11.0% of cases (Supplemental Table 2 ). The most frequent adverse effects were asthenia (25.7%), edema (11.0%), nausea or vomiting (10.0%), thoracic or abdominal or generalized pain (10%), fever (7.3%), dyspnea (7.6%), reduced appetite (7.4%), numbness (6.4%), and diarrhea (6.4%). Other rare adverse events included mucositis, handfoot syndrome, dyspnea, and headache (all ,3%). Hematologic events, namely, transitory anemia, neutropenia, and thrombocytopenia were observed in 34.8%, 20.2% and 11.9% of cases, respectively. Nine patients required GEM discontinuation because of adverse events. We found no relevant differences in terms of drug tolerability between patients treated with or without concomitant capecitabine and/or mitotane.
hENT1 and RRM1 as prognostic and predictive factors
Acknowledging the limited number of patients with clinical benefit, we sought to identify the potential predictive factors in the subgroup of 70 patients with available tumor samples. Compared with the entire group of 145 patients, this subgroup had received a similar treatment regimen and a superimposable PFS during treatment [median, 13 weeks (88 days)]. Representative examples for hENT1 and RRM1 immunostaining in normal and neoplastic adrenocortical FFPE samples are shown in Fig. 2 . For this evaluation, we used FFPE material from 65 primary tumors, 3 local recurrence cases, and 2 distant metastasis cases. Moreover, we had tissue available from multiple surgeries for 17 patients, in which we could investigate hENT1 and RRM1 staining over time. However, we did not observe any relevant differences in the single cases. Despite the positive results in other tumor entities, we also did not observe any substantial relationship between hENT1 staining and PFS during treatment (HR for progress, 0.99; 95% CI, 0.57 to 1.70; P = 0.97; Fig. 3A) . Similarly, no difference in terms of the best objective response to GEM-based therapy was found in patients with positive or negative hENT1 expression (progressive disease in 33 of 45 vs 16 of 25, respectively; P = 0.67, x 2 test). Examination of RRM1 revealed that RRM1 expression also did not influence PFS during treatment (HR, 0.84; 95% CI, 0.46 to 1.46; P = 0.52; Fig. 3B ). Patients with high RRM1 expression had a similar best objective response to GEM-based therapy compared with those with low RRM1 levels (progressive disease in 34 of 50 vs 16 of 20, respectively; P = 0.43, x 2 test). Furthermore, we investigated the association between the combination of hENT1 and RRM1 immunostaining and PFS during GEM-based therapy without identifying any relevant correlation (P = 0.99; Fig. 3C ). Finally, we analyzed the role of hENT1 and RRM1 in a large cohort of an additional 216 ACC samples (303 samples from 262 patients), 51 adenoma samples, and 18 normal adrenal gland samples (Supplemental Table 1 ). For hENT1, the staining in the cytoplasm was highly homogenous, as illustrated by a percentage of positive cells .50% in 86% of all samples (median, 75%; range, 20% to 100%). For RRM1, cytoplasmatic staining was also relatively homogenous, with a percentage of positive cells .50% in 76% of samples (median, 70%; range, 15% to 100%). hENT1m staining was positive in substantially fewer ACC cases (92 of 303; 30%) compared with the adenoma cases (36 of 51; 71%) or normal adrenal gland cases (11 of 18; 61%; P = 0.005, x 2 test for absolute values; Supplemental Fig. 2) . Considering all the ACC samples, hENT1 staining was only slightly inferior in tissue from distant metastasis (n = 30; 88% negative), local recurrence (n = 33; 70% negative), or primary tumor (n = 240; 67% negative; P = 0.058, x 2 test) cases.
Such differences were not observed for RRM1 expression. For the correlation analyses between immunostaining and general clinical outcome, only patients who had ACC with samples from primary tumors were considered (n = 240 of 262). Those patients with negative hENT1 staining had substantially shorter disease-specific survival (median, 30 vs 89 months; HR for specific death, 1.71; 95% CI, 1.18 to 2.29; P = 0.0033) and PFS after primary surgery (median, 8 vs 13 months; HR for progression, 1.44, 95% CI, 1.08 to 1.94; P = 0.0172; Fig. 4A and 4B ). The effect of hENT1 on disease-specific survival remained statistically significant on multivariate analysis, including ENSAT tumor stage, resection status, and Ki67 proliferation index (HR, 0.53; 95% CI, 0.33 to 0.85; P = 0.009). In contrast, no relevant relationship between the RRM1 staining levels and the general clinical outcome (either disease-specific survival or PFS after primary surgery) was observed.
Discussion
To the best of our knowledge, the present work not only represents the largest study of GEM-based chemotherapy of patients with advanced ACC (n = 145) but also, after the FIRM-ACT trial, the second largest study of pharmacological treatment of ACC (7, 23) . We have clearly demonstrated that this pharmacological approach is moderately active in clinical practice, with a disease control rate (disease stabilization or therapy response) in~30% of patients, with a clinical benefit (disease stabilization or response to therapy for $4 months) in~20%. This rate was inferior to the rate of 46% previously described in the prospective phase 2 trial (n = 28) (8). However, this is not a rare situation with subsequent real-world studies. Furthermore, it seemed to be inferior to the rates reported for etoposide, doxorubicin, cisplatin, and mitotane schema (disease control in 58.2% of cases) but similar to those shown for the streptozotocin plus mitotane regimen (disease control in 31.4% of cases) in the FIRM-ACT trial (7) . Finally, the response rates of GEM-based therapy resulted in superior to the rates demonstrated for linsitinib (23) (Supplemental Table 3 ). Although several influencing factors, such as different staging intervals, the retrospective nature of the present study, and the modalities and duration of concomitant mitotane, would prevent a direct comparison, we believe it could be helpful for placing these results into clinical context. Concerning the toxicity, we found a pattern superimposable onto that previously reported (8) , with severe drug-related adverse events in only 11% of patients, further confirming that GEM-based chemotherapy is generally very well tolerated. This and because promising "targeted" drug alternatives are missing, suggest that GEM-based chemotherapy remains a possible therapeutic option as salvage treatment of advanced ACC. Our data indicate (but cannot prove) that GEM should be combined with capecitabine, because the combination results in slightly better efficacy without additional toxicity. Furthermore, the subanalysis of the patients cotreated with mitotane suggested that this ACC-specific drug might be also a good combination partner if drug levels .14 mg/L can be achieved.
Moreover, we have provided, to the best of our knowledge, the first extensive evaluation of hENT1 and RRM1 protein expression in a large series of normal and neoplastic adrenocortical tissues. In particular, we evaluated their prognostic potential for general clinical outcomes in patients with ACC and their predictive role for the response to GEM-based chemotherapy. We have demonstrated that hENT1 membranous immunostaining, which is the most relevant indicator for protein expression of hENT1 (a nucleoside transporter), is significantly less frequent in ACC than in adrenocortical adenoma and normal adrenal glands. Furthermore, we found that hENT1 staining slightly decreased with disease progression and was significantly associated with prolonged disease-specific survival and PFS in patients who had ACC, thus potentially representing a molecular prognostic factor. These findings were in accordance with previous studies of some other cancer types (15, 26, 27) but in contrast to others (28) . Our present results could be of particular interest because the downregulation of hENT1 itself has been shown to be related to an altered epithelial mesenchymal transition, probably independently of its role as a drug transporter (29, 30) . Thus, hENT1 might also serve as an independent prognostic biomarker. To date, only a limited number of such molecular markers have been proposed, in addition to the Ki67 proliferation marker (31) (32) (33) (34) (35) . Accordingly, our present findings could be of particular relevance.
We also separately considered 70 patients who had ACC and had undergone GEM-based chemotherapy to investigate the predictive potential of hENT1/RRM1 expression for the sensitivity to therapy. We did not observe any substantial effects between the hENT1 or RRM1 staining results and PFS during treatment or the objective response to therapy. These findings are in contrast with previously reported data for hENT1 in other cancer types, such as pancreatic cancer (13) (14) (15) , biliary tract cancer (16), or bladder cancer (18) . However, other large studies of advanced pancreatic carcinoma also did not detect a relevant role for hENT1 immunostaining for predicting the sensitivity to GEMbased chemotherapy (36, 37) . Similarly, RRM1 has been recognized as a promising predictive biomarker in some studies (38) , but not in all (39, 40) . Even a combination of these two biomarkers did not allow for a reliable prediction of response to GEM-based chemotherapy in ACC, in contrast to previously reported results for pancreatic cancer (41) and cholangiocarcinoma (42) . These discrepancies might have resulted from several factors, including the different methods used to evaluate immunostaining [e.g., no standardized scoring protocol and/or differences in the antibodies, as previously outlined elsewhere (43) ] and the variability of molecular and clinical factors that might have influenced both the sensitivity to, and the treatment efficacy of, GEM-based chemotherapy itself. Other molecular mechanisms, such as the thymidylate synthase, the ribonucleotide reductase large subunit 2, or the activating enzyme deoxycytidine kinase, might be at least theoretically involved in the chemoresistance to GEM and might therefore behave synergistically with hENT1 and/or RRM1 (44, 45) . Furthermore, concomitant or parallel treatments (e.g., alternative drugs, such as mitotane and/or capecitabine), might have influenced the interval to progression during treatment. Another limitation of the present analysis was that both molecular markers were assessed mostly from tumor specimens from primary tumors and not from tumor biopsy specimens before GEM-based therapy. However, we believe our data have demonstrated that hENT1 and RRM1 expression, either alone or combined, cannot serve as robust predictive biomarkers of GEM-based therapy in ACC.
Conclusions
GEM-based chemotherapy is moderately active but generally well-tolerated against advanced-disease ACC. Furthermore, no reliable predictive molecular factors are yet available. Thus, we suggest GEM-based chemotherapy, preferentially in association with mitotane, as a salvage treatment for selected patients with advanced ACC.
Acknowledgments
The authors thank Martina Zink for excellent technical support and Michaela Haaf for coordinating the ENSAT ACC Registry in Wuerzburg. 
